<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">1419609</article-id>
      <article-id pub-id-type="pmc">1977420</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Baars</surname>
            <given-names>J. W.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coenen</surname>
            <given-names>J. L.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wagstaff</surname>
            <given-names>J.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van der Valk</surname>
            <given-names>P.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinedo</surname>
            <given-names>H. M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.</aff>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>1992</year>
      </pub-date>
      <volume>66</volume>
      <issue>4</issue>
      <fpage>698</fpage>
      <lpage>699</lpage>
      <abstract>
        <p>Interleukin-2 (IL-2) is now registered for the treatment of renal cell carcinoma in a number of European countries. The subcutaneous (sc) route of administration is being used increasingly because of its better toxicity profile compared with higher dose intravenous (iv) protocols. We report here a patient who developed a lobular panniculitis at the site of sc IL-2 injection which prevents continuation of sc therapy. Subsequent administration of the same IL-2 dose by iv injection caused recurrence of the problem again necessitating discontinuation of IL-2 treatment.</p>
        <sec sec-type="scanned-figures">
          <title>Images</title>
          <fig id="F1">
            <label>Figure 1</label>
            <graphic xlink:href="brjcancer00062-0094-a" xlink:role="698"/>
          </fig>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <supplementary-material content-type="scanned-pages">
      <graphic xlink:href="brjcancer00062-0094.tif" xlink:title="scanned-page" xlink:role="698" mimetype="image" mime-subtype="tiff"/>
      <graphic xlink:href="brjcancer00062-0095.tif" xlink:title="scanned-page" xlink:role="699" mimetype="image" mime-subtype="tiff"/>
    </supplementary-material>
  </body>
</article>
</pmc-articleset>
